TransMedics Group (NASDAQ:TMDX) Stock Price Down 6.1%

TransMedics Group, Inc. (NASDAQ:TMDX) was down 6.1% during mid-day trading on Wednesday . The company traded as low as $87.56 and last traded at $87.65. Approximately 447,535 shares changed hands during mid-day trading, a decline of 34% from the average daily volume of 681,154 shares. The stock had previously closed at $93.31.

Analyst Upgrades and Downgrades

TMDX has been the subject of a number of analyst reports. Oppenheimer raised their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Piper Sandler initiated coverage on TransMedics Group in a research note on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price target for the company. JPMorgan Chase & Co. increased their price objective on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Finally, Morgan Stanley boosted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $102.00.

TransMedics Group Trading Down 6.5 %

The company has a market cap of $2.85 billion, a price-to-earnings ratio of -117.14 and a beta of 1.99. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The business’s 50 day moving average price is $83.01 and its 200-day moving average price is $72.77.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $68.49 million. During the same quarter last year, the business earned ($0.21) EPS. The company’s quarterly revenue was up 158.6% compared to the same quarter last year. On average, equities analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Insider Activity

In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,044,932.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 15,512 shares of the company’s stock in a transaction that occurred on Tuesday, April 9th. The shares were sold at an average price of $90.45, for a total value of $1,403,060.40. Following the completion of the transaction, the insider now directly owns 25,185 shares in the company, valued at approximately $2,277,983.25. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $7,044,932.83. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 115,408 shares of company stock worth $9,802,401. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Harbour Capital Advisors LLC raised its position in shares of TransMedics Group by 1.7% during the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock worth $627,000 after acquiring an additional 140 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in TransMedics Group by 45.1% during the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock worth $41,000 after purchasing an additional 169 shares during the last quarter. Belpointe Asset Management LLC lifted its position in shares of TransMedics Group by 51.6% in the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock worth $42,000 after purchasing an additional 190 shares during the period. RiverPark Advisors LLC boosted its stake in shares of TransMedics Group by 19.5% in the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after purchasing an additional 215 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of TransMedics Group by 2.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,512 shares of the company’s stock worth $896,000 after buying an additional 288 shares during the period. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.